Post Market Clinical Follow-up Investigation to Evaluate Performance and Safety on Pressure Ulcers, PU, When Using Exufiber as Intended
Launched by MOLNLYCKE HEALTH CARE AB · Aug 22, 2014
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Both gender ≥18 years old.
- • 2. Subjects with Stage 2, 3 or 4 cavity pressure ulcer (acc to EPUAP)
- • 3. Exuding pressure ulcer
- • 4. Signed Informed Consent.
- Exclusion Criteria:
- • 1. Known allergy/hypersensitivity to the dressing.
- • 2. Infected wounds, (2 signs of infection/local inflammation and a positive swab)
- • 3. Stage 1 PU
- • 4. Dry wounds
- • 5. Subjects who will have problems following the protocol
- • 6. Subjects included in other ongoing clinical investigation at present or during the past 30 days
About Molnlycke Health Care Ab
Mölnlycke Health Care AB is a global medical solutions company specializing in the development and manufacturing of innovative wound care and surgical products. With a strong commitment to enhancing patient outcomes, Mölnlycke combines extensive clinical expertise with advanced technology to deliver high-quality medical devices and solutions. The company operates with a focus on sustainability and collaboration with healthcare professionals, ensuring that their products meet the evolving needs of patients and healthcare systems worldwide. Through rigorous clinical trials and research, Mölnlycke continues to advance the field of healthcare, aiming to improve healing processes and promote patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussel, , Belgium
Gent, , Belgium
Kortrijk, , Belgium
Helsinki, , Finland
Patients applied
Trial Officials
Hilde Beele, prof. dr
Principal Investigator
University Hospital Gent, Belgium
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials